Section Arrow
Quote
SRPT.NASDAQ
- Sarepta Therapeutics
Quotes are at least 15-min delayed:2026/06/06 03:38 EDT
Regular Hours
Last
 15.75
-0.91 (-5.46%)
Day High 
16.69 
Prev. Close
16.66 
1-M High
23.49 
Volume 
2.74M 
Bid
15.7
Ask
15.8
Day Low
15.66 
Open
16.59 
1-M Low
15.95 
Market Cap 
1.76B 
Currency 美元 
P/E 45 
%Yield -- 
10-SMA 16.9 
20-SMA 17.71 
50-SMA 20.04 
52-W High 43.9156 
52-W Low 10.415 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.35/2.52
Enterprise Value
2.79B
Balance Sheet
Book Value Per Share
14.26
Cash Flow
Cash Flow Yield
0.10
Income Statement
Total Revenue
2.20B
Operating Revenue Per Share
10.47
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
BCDABioCardia Inc.1.03+0.111+12.08%-- 
BGMSBio Green Med Solution Inc1.5+0.44+41.51%0.3PE
CMNDClearmind Medicine Inc.3.98+1.07+36.77%-- 
ADTXAditxt Inc.0.0621-0.0149-19.35%-- 
RXRXRecursion Pharmaceuticals3.315-0.485-12.76%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.